Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
- Conditions
- Acromegaly
- Registration Number
- NCT05149495
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described.
Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Study of the clinical and biological evolution, after discontinuation of treatment with somatostatin analogues, of acromegalic patients with recurrence after surgery. Files analysed retrospectively from January 01, 2000 to September 01, 2021 will be examined]
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg
🇫🇷Strasbourg, France